CARDIFF ONCOLOGY, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested
CARDIFF ONCOLOGY, INC. (CRDF) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested of $295.37 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-06.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested · last filed 2019-03-06
- CARDIFF ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for the quarter ending 2018-03-31 was $266.46K, a 53.85% decline year-over-year.
- CARDIFF ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for the quarter ending 2017-12-31 was $2.11K.
- CARDIFF ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for the quarter ending 2017-09-30 was $65.59K.
- CARDIFF ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for the quarter ending 2017-06-30 was $2.83K.
- CARDIFF ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for fiscal 2018 was $295.37K, a 54.41% decline from fiscal 2017.
- CARDIFF ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for fiscal 2017 was $647.88K, a 120.53% increase from fiscal 2016.
- CARDIFF ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for fiscal 2016 was $293.78K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 12 month |
|---|---|---|---|---|
| 2018-12-31 | $295.37K 10-K · filed 2019-03-06 | |||
| 2018-03-31 | $266.46K 10-Q · filed 2018-05-08 | $268.57K derived: sum of 2 quarters · filed 2019-03-06 | $334.17K derived: sum of 3 quarters · filed 2019-03-06 | $337.00K derived: sum of 4 quarters · filed 2019-03-06 |
| 2017-12-31 | $2.11K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $67.70K derived: sum of 2 quarters · filed 2019-03-06 | $70.53K derived: sum of 3 quarters · filed 2019-03-06 | $647.88K 10-K · filed 2019-03-06 |
| 2017-09-30 | $65.59K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $68.42K derived: sum of 2 quarters · filed 2017-11-09 | $645.77K 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $2.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $580.18K 10-Q · filed 2017-08-09 | ||
| 2017-03-31 | $577.35K 10-Q · filed 2017-05-10 | |||
| 2016-12-31 | $293.78K 10-K · filed 2018-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |